Recruiting

CHORDS

Sponsor:

University of Rochester

Code:

NCT07263074

Conditions

Myeloid Malignancy

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

CHORDS

Study Details

Brief summary:

This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \[CHORDS\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).

Conditions

Myeloid Malignancy

Study ID

NCT07263074

Start date

Jan 15, 2026

Status verified date

Jul, 2026

Completion date

Jun 30, 2028

Anticipated

Primary completion date

Jun 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Patients

Inclusion criteria:

1. Age >21 years old
2. Diagnosis of myeloid cancer (e.g. AML, MDS, myelofibrosis, CML, or MDS/MPN)
3. Being considered for alloHCT
4. Able to provide informed consent
5. Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated.

Exclusion criteria 1) Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures

Caregivers

Inclusion criteria:

1. Age >18 years old
2. Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters."
3. Caregiver may be paid/professional or informal caregiver
4. Able to provide informed consent
5. Able to speak English

Exclusion Criteria:

1\) None

Hematologists

Inclusion criteria:

1\) Hematologists of the patients who agree to enroll on the study who are part of WCI.

Exclusion criteria

1\) None

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Intervention (CHORDS)

The CHORDS intervention consists of 1) digital stories created by individuals who previously underwent consultation for alloHCT and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling (BWS).

no intervention: Usual Care

Patients randomized to the usual care arm will receive standard of care. Patients (and their caregivers when available) randomized to usual care will not participate in CHORDS. Patients and caregivers will complete baseline (T1) and post-alloHCT office visit (T3, T4, T5) assessments.

Interventions

CHORDS

The CHORDS intervention consists of 1) digital stories created by individuals who previously underwent consultation for alloHCT and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling (BWS).

Primary outcome measure

  • Percentage of Participants Retained (Feasibility - Retention Rate) [ Time Frame: From enrollment (Day -30 to Day 0) to 2 weeks post-alloHCT office visit (Day 9-19) ]

Central Contacts and Locations

Central contacts

Rachel Rodenbach, MD, MS

585-275-5830rachel_rodenbach@urmc.rochester.edu

Becky Gravenstede, BA

585-727-4728becky_gravenstede@urmc.rochester.edu

Locations

University of Rochester

Recruiting

Rochester, New York, United States, 14642

Contacts

Rachel Rodenbach

585-275-5830rachel_rodenbach@urmc.rochester.edu

Principal Investigator:

Rachel Rodenbach

More Information

Sponsor

University of Rochester

Last update posted

Jul 6, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Rochester on 2026-07-06.